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not been well studied, we sought to determine the efficacy and safety of these two
approaches in the management of patients with symptomatic pericardial effusion (PE).
Methods: We conducted a retrospective chart review of 193 consecutive patients who
underwent percutaneous pericardiocentesis or surgical pericardial drainage between
2007 and 2009 at our institution. In addition to baseline demographics, intra-procedural
and immediate post-procedural mechanical, cardiovascular and pulmonary
complications were assessed for each patient. Recurrence was defined as
reaccumulation of pericardial fluid requiring repeat drainage within a 3-month period.
Results: Between 2007 and 2009, 121 (62.9%) patients underwent pericardiocentesis
and 72 (37.3%) had surgical drainage for symptomatic PE. There was no significant
difference between the groups in age, sex, BMI, history of cancer,chronic kidney
disease, or prior myocardial infarction.The etiology of the effusions included post-
cardiac surgery (32.1%), malignant (17.1%), idiopathic (16.6%), iatrogenic (11.4%),
inflammatory (5.2%), and uremic (3.1%). In the pericardiocentesis group, 35 of 121
patients (28.9%) required repeat procedures compared to 2/72 (2.8%) patients in the
surgical group (OR 14.2, 95% CI [3.3-61.3], p<.0001). Nineteen patients (19/72,
26.4%) in the surgical group had a procedural complication compared to 6 patients
(6/121, 4.9%) in the pericardiocentesis group (OR 6.9, CI[ 2.6-18.2 ], p<0.0001).
Conclusion: In a single center series of symptomatic pericardial effusions, compared
to open surgical drainage, percutaneous pericardiocentesis is associated with a higher
rate of effusion recurrence requiring repeat drainage, but a lower rate of procedural
complications. Future studies will compare the long-term outcomes of
pericardiocentesis versus surgical drainage for pericardial effusion.
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Background: Multiple paravalvular leaks (MPL) are associated with increased rate
of hemolysis and congestive heart failure (CHF) compared with single and small leaks.
Methods: We describe the result of consecutive patients (P) with MPL, treated with
Amplatzer Vascular Plug III (AVP III) from December 2008 to December 2010. The
indication for paravalvular leaks transcatheter closure was: congestive heart failure
(CHF), hemolysis or both. Each patient was reviewed by at least three physicians, at
least one of which was a surgeon, regarding the risk of reoperation.
Results: A total of 22 P, were included. Of the total population 64% were male. The
mean age was 65 +/- 11 years. Fourteen P (64%) had pulmonary hypertension with a
mean pulmonary artery pressure of 65 +/- 32 mmHg and 82% were in NYHA
functional class III - IV. The mean logistic Euroscore was 18 +/- 17. The most common
indication for intervention was CHF + hemolysis (64%), isolated CHF in 4P (18%)
and hemolysis in 4 P (18%) . The mean number of previous surgery was 2 +/-1, with
a mean number of leaks of 2.5 +/- 0.5. Sixteen P (72%) had mitral MPL, 3 P (14%)
had aortic MPL and 3 P (14%) had both mitral and aortic MPL. Eighty six percent of
the MPLs were on mechanical prostheses. Success rate of AVP III implantation in all
leaks was 86%, in fourteen of them (63%) closure was achieved in only 1 procedure.
The repair was incomplete in 2 P (9%) and unsuccessful in 1 P (4%). Residual leak <
2 was obtained in 16 P (73%) with no mayor complications. No procedure related
deaths were reported. The mean follow up was 285 +/- 227 days. Functional class was
improved in 13 P (59%). Reoperation was required in 3 P (14). There were 3 cardiac
deaths, 2 of them after surgical reoperation.
Conclusion: The closure of the MPL with AVP III is a feasible procedure with a high
success rate of device implantation and low procedural mortality rate, are technically
challenging, with acceptable clinical improvement.
TCT-725
Interventional Perspective of Tricuspid Regurgitation: Heterotopic
Percutaneous Valve Implantation From Preclinical Trials to First-in-Man
Application
Alexander Lauten, Markus Ferrari, Hans R Figulla
University Heart Center Jena, Jena, Germany
Background: Heterotopic valve implantation into the caval veins has been suggested
to treat venous congestion in severe tricuspid regurgitation (TR). We report our
experience with this approach from basic preclinical studies to first human treatment.
Methods: Proof-of-concept studies were performed in a TR-sheep model. Following
the induction of TR, two valves were implanted into the superior and inferior caval
(IVC) vein resulting in a significant decrease of the ventricular wave(ν-wave) from
16.2±2.33 to 13.9±2.97mmHg and a significant rise of cardiac output from 2.9±1.16
to 4.20±0.84l/min. Valve function was documented after 6 month follow-up. Device
position and function were verified at autopsy.
Results: Based on these promising results, the first-in-man concept application was
performed for compassionate treatment in an inoperable 79-year-old patient (3 previous
heart surgeries, EuroScore 30%). In this patient, a self-expanding pericardial tissue
valve was implanted in a transcatheter approach in the IVC and anchored at the cavo-
atrial junction just above the hepatic vein inflow. After deployment, excellent device
function and valvular competence were confirmed with full systolic closure and
diastolic opening. Hemodynamics confirmed a nearly abolished ν-wave in the IVC
from 29/19 to 19/12mmHg and a decrease of mean pressure from 19 to 16mmHg.
Valve function remained excellent during the first 8 weeks of follow-up. The patient
experienced improved physical capacity and was able to resume off-bed acitivities.
There was no recurrence of RV failure and a partial reduction of ascites. She was
discharged from hospital into a rehabilitation program.
Conclusion: Transcatheter caval valve implantation is feasible and results in an
immediate abolition of IVC regurgitation in severe TR with midterm clinical
improvement. Thus, in selected non-surgical patients with TR this concept may become
an option to treat venous regurgitation and improve hepatic congestion. Further
experience with longer follow-up is required to evaluate the long-term clinical benefit.
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Background: One of the causes of migraine is arterial insufficiency of the brain that
is most often caused by vascular hypoplasia, a congenital systemic lesion.
Methods: 42 patients aged 30-57 (average age 41) suffering from severe migraine and
vestibular disorders, and having long been under ineffective conservative therapy, were
examined and operated on. In all cases the investigation plan included CT, MRI, SG,
REG, and MUGA. Patient selection criteria were the absence of pronounced
atherosclerotic lesions of intracranial branches and the presence of hypoplasia (anterior
cerebral artery trunk diameter less than 0.9 mm, middle cerebral artery trunk diameter
less than 2.4 mm.). CT and MRI revealed: enlargement of the subarachnoid space in
12 (28.57%) cases, blurred relief of convexital surface of the hemispheres in 11
(26.19%) cases, blurred boundaries of gray and white matter of the brain in 40
(95.23%) cases, hydrocephalus phenomenon in 31 (73.80%) cases. According to
MUGA, all 42 patients did not have any pronounced atherosclerotic lesions of
intracranial branches, 8 (19.04%) patients had hemodynamically insignificant stenosis
of extracranial vessels. For transcatheter laser irradiation low-energy laser systems
were used.
Results: Immediate angiographic outcome, i.e. persistent expansion of intracranial
blood vessels back to the norm after transcatheter laser irradiation, was obtained in 40
(95.24%) cases. Good clinical outcome, i.e. almost complete disappearance of migraine
and vestibular disorders, was obtained in 37 (88.09%) cases. Satisfactory clinical
outcome, i.e. incomplete disappearance of migraine and vestibular disorders, was
observed in 5 (11.90%) cases. 6-12 months after the laser treatment CT and MRI
revealed improved visualization of brain structures in 38 (90.48%) cases, reduction of
hydrocephalus phenomena in 28 (90.32%) cases. Improved cerebral blood flow was
observed in 41 (97.62%) cases.
Conclusion: The results obtained show high efficiency of the method of transcatheter
laser irradiation in the treatment of migraine accompanied by brain vessels hypoplasia.
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Background: Transcatheter aortic valve implantation (TAVI) is a rapidly evolving
technique for high-risk patients with significant aortic stenosis (AS). Using the
Medtronic CoreValve Prosthesis (MCV) the trans-femoral (TF) access is widely
accepted to be the first choice whereas the left subclavian artery (SA) is used as an
alternative AW. Contrast-enhanced multi-slice computed tomography (MSCT) is
established for non-invasive evaluation of AW in TAVI. It is not known, how many
patients with AS fail the anatomical criteria and therefore are not treatable using TAVI
with the MCV. Aim of the study was to identify the proportion of TAVI patients not
eligible using these widely used AW.
Methods: We retrospectively analyzed 533 patients with severe AS (81.08+/-6.32
years, 248 men) scheduled for TAVI between 07/2008 and 10/2010. In all patients, a
contrast-enhanced MSCT was performed. The femoral AW were evaluated in all
patients. TF AW was classified as possible, if 3 conditions were fulfilled: diameter >
6 mm, maximal moderate calcification and angulation. Patients were classified as
treatable if one side was acceptable. In the remaining patients, evaluation of the SA
was performed. The trans-subclavian AW was accepted, when the following conditions
were present: diameter > 6 mm, low calcification and maximal moderate angulation
till the level of the upper thoracic outlet.
Results: Using the right TF AW, patients were formally treatable in 55.9% compared
to 47.5% using the left TF AW. Taking both sides into account, the number of patients
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